Insertion of Cochlear Implant Electrode Array Using the Underwater Technique for Preserving Residual Hearing.

Objective: To describe a method of cochlear implantation in which the opening of the cochlea and the electrode array insertion are performed under water (underwater technique). Study Design: Retrospective patient review. Setting: Academic tertiary referral center. Patients: Fifteen implantations in children and adult patients with residual hearing at the frequencies 250, 500, and 1000 Hz on the unaided preoperative pure-tone audiometry were included in this study. Intervention(s): Cochlear implantation with a conventional full-length electrode, in which the opening of the cochlea and the electrode array insertion are performed after the tympanic cavity was filled with body-temperature Ringer solution. Main Outcome Measure(s): Changes on residual hearing 6 to 8 weeks after surgery and at subsequent follow-up appointments were analyzed. Preservation of residual hearing was defined as measurable postoperative threshold at the frequencies 250, 500, and 1000 Hz. Results: Overall postimplant hearing preservation 6 to 8 weeks after implantation was achieved in 13 of the patients (87%). Subsequent follow-up was performed on average 15.2 months after surgery (range, 7-32) in 14 out of 15 patients. At this late postoperative evaluation preservation of hearing was recorded in nine patients (64%), whereas in the remaining five patients (36%) no residual hearing was measured. Conclusion: The underwater technique offers a reliable nontraumatic method for electrode array insertions during cochlear implantation. The method respects the physiology of the cochlea und minimizes the pressure variations during cochlear opening and implantation. Copyright (C) 2016 by Otology & Neurotology, Inc. Image copyright (C) 2010 Wolters Kluwer Health/Anatomical Chart Company

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/1UJhpdf
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1LJ0vcR
via IFTTT

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1067745

Authors: Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ

Abstract
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of various immunotherapeutic strategies. High frequencies of tumor-specific CD8(+) T cells alone, however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of tumor-specific CD8(+) T cells in melanoma patients upon dendritic cell vaccination by measuring multiple T cell effector functions considered crucial for anticancer immunity, including the expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-specific CD8(+) T cells in several patients and dendritic cell therapy was able to improve the functionality of these pre-existing tumor-specific CD8(+) T cells. Generated multifunctional CD8(+) T cell responses could persist for up to ten years and within the same patient functionality could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC vaccination highly functional CD8(+) T cells were only detected in patients displaying prolonged overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8(+) T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in vivo.

PMID: 26942087 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2vH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrvrn
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QzkzhY
via IFTTT

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Oncoimmunology. 2016;5(1):e1068495

Authors: Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B

Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8(+) T lymphocytes in experimental melanoma.

PMID: 26942089 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH078
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ID6
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21eziAo
via IFTTT

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1067745

Authors: Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ

Abstract
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of various immunotherapeutic strategies. High frequencies of tumor-specific CD8(+) T cells alone, however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of tumor-specific CD8(+) T cells in melanoma patients upon dendritic cell vaccination by measuring multiple T cell effector functions considered crucial for anticancer immunity, including the expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-specific CD8(+) T cells in several patients and dendritic cell therapy was able to improve the functionality of these pre-existing tumor-specific CD8(+) T cells. Generated multifunctional CD8(+) T cell responses could persist for up to ten years and within the same patient functionality could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC vaccination highly functional CD8(+) T cells were only detected in patients displaying prolonged overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8(+) T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in vivo.

PMID: 26942087 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2vH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXru6X
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QzkzhW
via IFTTT

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Oncoimmunology. 2016;5(1):e1068495

Authors: Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B

Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8(+) T lymphocytes in experimental melanoma.

PMID: 26942089 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH078
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5FXO
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21eziAk
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrsvX
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QzkB9D
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ImH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21ezfEE
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXru6R
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QzkzhS
via IFTTT

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Oncoimmunology. 2016;5(1):e1104448

Authors: Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N

Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the PDCD1 promoter. These PD-1(neg) clones were of lower avidity than their PD-1(pos) counterparts, suggesting that high-affinity-specific T cell clones unable to express PD-1 are not or rarely present in peripheral blood, as they are probably eliminated by negative selection, due to their high reactivity. We also documented the existence of such PD-1(neg) T cell clones in melanoma tumor-infiltrating lymphocytes (TIL), which also exhibited a lower functional avidity than PD-1(pos) TIL clones. This clearly shows that PD-1 expression identifies antigen-specific T cell clonotypes of high functional avidity. Finally, we demonstrated that PD-1 blockade during the in vitro selection process of Melan-A-specific T cells favored the amplification of higher avidity T cell clonotypes. This preferential amplification of high-avidity memory T cells upon PD-1 blockade resonates with the expansion of reactive T cells, including neo-antigen-specific T cells observed in anti-PD-1-treated patients. This feature should also be a useful biomarker of clinical efficiency, while providing new insights for adoptive transfer treatments.

PMID: 26942093 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH07k
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21P0jQz
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21ezfoq
via IFTTT

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Oncoimmunology. 2016;5(1):e1104448

Authors: Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N

Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the PDCD1 promoter. These PD-1(neg) clones were of lower avidity than their PD-1(pos) counterparts, suggesting that high-affinity-specific T cell clones unable to express PD-1 are not or rarely present in peripheral blood, as they are probably eliminated by negative selection, due to their high reactivity. We also documented the existence of such PD-1(neg) T cell clones in melanoma tumor-infiltrating lymphocytes (TIL), which also exhibited a lower functional avidity than PD-1(pos) TIL clones. This clearly shows that PD-1 expression identifies antigen-specific T cell clonotypes of high functional avidity. Finally, we demonstrated that PD-1 blockade during the in vitro selection process of Melan-A-specific T cells favored the amplification of higher avidity T cell clonotypes. This preferential amplification of high-avidity memory T cells upon PD-1 blockade resonates with the expansion of reactive T cells, including neo-antigen-specific T cells observed in anti-PD-1-treated patients. This feature should also be a useful biomarker of clinical efficiency, while providing new insights for adoptive transfer treatments.

PMID: 26942093 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH07k
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ImB
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QzkB9z
via IFTTT

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology. 2016;5(1):e1057388

Authors: Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M

Abstract
The immune microenvironment of the brain differs from that of other organs and the role of tumor-infiltrating lymphocytes (TILs) in brain metastases (BM), one of the most common and devastating complication of cancer, is unclear. We investigated TIL subsets and their prognostic impact in 116 BM specimens using immunohistochemistry for CD3, CD8, CD45RO, FOXP3, PD1 and PD-L1. The Immunoscore was calculated as published previously. Overall, we found TIL infiltration in 115/116 (99.1%) BM specimens. PD-L1 expression was evident in 19/67 (28.4%) BM specimens and showed no correlation with TIL density (p > 0.05). TIL density was not associated with corticosteroid administration (p > 0.05). A significant difference in infiltration density according to TIL subtype was present (p < 0.001; Chi Square); high infiltration was most frequently observed for CD3+ TILs (95/116; 81.9%) and least frequently for PD1+ TILs (18/116; 15.5%; p < 0.001). Highest TIL density was observed in melanoma, followed by renal cell cancer and lung cancer BM (p < 0.001). The density of CD8(+) TILs correlated positively with the extent of peritumoral edema seen on pre-operative magnetic resonance imaging (p = 0.031). The density of CD3+ (15 vs. 6 mo; p = 0.015), CD8(+) (15 vs. 11 mo; p = 0.030) and CD45RO+ TILs (18 vs. 8 mo; p = 0.006) showed a positive correlation with favorable median OS times. Immunoscore showed significant correlation with survival prognosis (27 vs. 10 mo; p < 0.001). The prognostic impact of Immunoscore was independent from established prognostic parameters at multivariable analysis (HR 0.612, p < 0.001). In conclusion, our data indicate that dense TILs infiltrates are common in BM and correlate with the amount of peritumoral brain edema and survival prognosis, thus identifying the immune system as potential biomarker for cancer patients with CNS affection. Further studies are needed to substantiate our findings.

PMID: 26942067 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxGZQL
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrunx
via IFTTT

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology. 2016;5(1):e1057388

Authors: Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M

Abstract
The immune microenvironment of the brain differs from that of other organs and the role of tumor-infiltrating lymphocytes (TILs) in brain metastases (BM), one of the most common and devastating complication of cancer, is unclear. We investigated TIL subsets and their prognostic impact in 116 BM specimens using immunohistochemistry for CD3, CD8, CD45RO, FOXP3, PD1 and PD-L1. The Immunoscore was calculated as published previously. Overall, we found TIL infiltration in 115/116 (99.1%) BM specimens. PD-L1 expression was evident in 19/67 (28.4%) BM specimens and showed no correlation with TIL density (p > 0.05). TIL density was not associated with corticosteroid administration (p > 0.05). A significant difference in infiltration density according to TIL subtype was present (p < 0.001; Chi Square); high infiltration was most frequently observed for CD3+ TILs (95/116; 81.9%) and least frequently for PD1+ TILs (18/116; 15.5%; p < 0.001). Highest TIL density was observed in melanoma, followed by renal cell cancer and lung cancer BM (p < 0.001). The density of CD8(+) TILs correlated positively with the extent of peritumoral edema seen on pre-operative magnetic resonance imaging (p = 0.031). The density of CD3+ (15 vs. 6 mo; p = 0.015), CD8(+) (15 vs. 11 mo; p = 0.030) and CD45RO+ TILs (18 vs. 8 mo; p = 0.006) showed a positive correlation with favorable median OS times. Immunoscore showed significant correlation with survival prognosis (27 vs. 10 mo; p < 0.001). The prognostic impact of Immunoscore was independent from established prognostic parameters at multivariable analysis (HR 0.612, p < 0.001). In conclusion, our data indicate that dense TILs infiltrates are common in BM and correlate with the amount of peritumoral brain edema and survival prognosis, thus identifying the immune system as potential biomarker for cancer patients with CNS affection. Further studies are needed to substantiate our findings.

PMID: 26942067 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxGZQL
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5Ja7
via IFTTT

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1057673

Authors: Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ

Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42-0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.

PMID: 26942068 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZpQx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrvrD
via IFTTT

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology. 2016;5(1):e1057388

Authors: Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M

Abstract
The immune microenvironment of the brain differs from that of other organs and the role of tumor-infiltrating lymphocytes (TILs) in brain metastases (BM), one of the most common and devastating complication of cancer, is unclear. We investigated TIL subsets and their prognostic impact in 116 BM specimens using immunohistochemistry for CD3, CD8, CD45RO, FOXP3, PD1 and PD-L1. The Immunoscore was calculated as published previously. Overall, we found TIL infiltration in 115/116 (99.1%) BM specimens. PD-L1 expression was evident in 19/67 (28.4%) BM specimens and showed no correlation with TIL density (p > 0.05). TIL density was not associated with corticosteroid administration (p > 0.05). A significant difference in infiltration density according to TIL subtype was present (p < 0.001; Chi Square); high infiltration was most frequently observed for CD3+ TILs (95/116; 81.9%) and least frequently for PD1+ TILs (18/116; 15.5%; p < 0.001). Highest TIL density was observed in melanoma, followed by renal cell cancer and lung cancer BM (p < 0.001). The density of CD8(+) TILs correlated positively with the extent of peritumoral edema seen on pre-operative magnetic resonance imaging (p = 0.031). The density of CD3+ (15 vs. 6 mo; p = 0.015), CD8(+) (15 vs. 11 mo; p = 0.030) and CD45RO+ TILs (18 vs. 8 mo; p = 0.006) showed a positive correlation with favorable median OS times. Immunoscore showed significant correlation with survival prognosis (27 vs. 10 mo; p < 0.001). The prognostic impact of Immunoscore was independent from established prognostic parameters at multivariable analysis (HR 0.612, p < 0.001). In conclusion, our data indicate that dense TILs infiltrates are common in BM and correlate with the amount of peritumoral brain edema and survival prognosis, thus identifying the immune system as potential biomarker for cancer patients with CNS affection. Further studies are needed to substantiate our findings.

PMID: 26942067 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxGZQL
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ITG
via IFTTT

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1057673

Authors: Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ

Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42-0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.

PMID: 26942068 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZpQx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXru75
via IFTTT

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1057673

Authors: Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ

Abstract
Melanoma patients with regional metastatic disease are at high risk for recurrence and metastatic disease, despite radical lymph node dissection (RLND). We investigated the immunologic response and clinical outcome to adjuvant dendritic cell (DC) vaccination in melanoma patients with regional metastatic disease who underwent RLND with curative intent. In this retrospective study, 78 melanoma patients with regional lymph node metastasis who underwent RLND received autologous DCs loaded with gp100 and tyrosinase and were analyzed for functional tumor-specific T cell responses in skin-test infiltrating lymphocytes. The study shows that adjuvant DC vaccination in melanoma patients with regional lymph node metastasis is safe and induced functional tumor-specific T cell responses in 71% of the patients. The presence of functional tumor-specific T cells was correlated with a better 2-year overall survival (OS) rate. OS was significantly higher after adjuvant DC vaccination compared to 209 matched controls who underwent RLND without adjuvant DC vaccination, 63.6 mo vs. 31.0 mo (p = 0.018; hazard ratio 0.59; 95%CI 0.42-0.84). Five-year survival rate increased from 38% to 53% (p < 0.01). In summary, in melanoma patients with regional metastatic disease, who are at high risk for recurrence and metastatic disease after RLND, adjuvant DC vaccination is well tolerated. It induced functional tumor-specific immune responses in the majority of patients and these were related to clinical outcome. OS was significantly higher compared to matched controls. A randomized clinical trial is needed to prospectively validate the efficacy of DC vaccination in the adjuvant setting.

PMID: 26942068 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZpQx
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ITu
via IFTTT

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1067745

Authors: Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ

Abstract
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of various immunotherapeutic strategies. High frequencies of tumor-specific CD8(+) T cells alone, however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of tumor-specific CD8(+) T cells in melanoma patients upon dendritic cell vaccination by measuring multiple T cell effector functions considered crucial for anticancer immunity, including the expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-specific CD8(+) T cells in several patients and dendritic cell therapy was able to improve the functionality of these pre-existing tumor-specific CD8(+) T cells. Generated multifunctional CD8(+) T cell responses could persist for up to ten years and within the same patient functionality could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC vaccination highly functional CD8(+) T cells were only detected in patients displaying prolonged overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8(+) T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in vivo.

PMID: 26942087 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2vH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrvrp
via IFTTT

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Oncoimmunology. 2016;5(1):e1068495

Authors: Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B

Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8(+) T lymphocytes in experimental melanoma.

PMID: 26942089 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH078
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5FY1
via IFTTT

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1067745

Authors: Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ

Abstract
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of various immunotherapeutic strategies. High frequencies of tumor-specific CD8(+) T cells alone, however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of tumor-specific CD8(+) T cells in melanoma patients upon dendritic cell vaccination by measuring multiple T cell effector functions considered crucial for anticancer immunity, including the expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-specific CD8(+) T cells in several patients and dendritic cell therapy was able to improve the functionality of these pre-existing tumor-specific CD8(+) T cells. Generated multifunctional CD8(+) T cell responses could persist for up to ten years and within the same patient functionality could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC vaccination highly functional CD8(+) T cells were only detected in patients displaying prolonged overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8(+) T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in vivo.

PMID: 26942087 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2vH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrvrn
via IFTTT

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Oncoimmunology. 2016;5(1):e1068495

Authors: Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B

Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8(+) T lymphocytes in experimental melanoma.

PMID: 26942089 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH078
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ID6
via IFTTT

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Oncoimmunology. 2016;5(1):e1067745

Authors: Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ

Abstract
Cytotoxic T cells are considered crucial for antitumor immunity and their induction is the aim of various immunotherapeutic strategies. High frequencies of tumor-specific CD8(+) T cells alone, however, are no guarantee for long-term tumor control. Here, we analyzed the functionality of tumor-specific CD8(+) T cells in melanoma patients upon dendritic cell vaccination by measuring multiple T cell effector functions considered crucial for anticancer immunity, including the expression of pro-inflammatory cytokines, chemokines and cytotoxic markers (IFNγ, TNFα, IL-2, CCL4, CD107a). We identified small numbers of multifunctional (polyfunctional) tumor-specific CD8(+) T cells in several patients and dendritic cell therapy was able to improve the functionality of these pre-existing tumor-specific CD8(+) T cells. Generated multifunctional CD8(+) T cell responses could persist for up to ten years and within the same patient functionality could vary greatly for the different vaccination antigens. Importantly, after one cycle of DC vaccination highly functional CD8(+) T cells were only detected in patients displaying prolonged overall survival. Our results shed light on the dynamics of multifunctional tumor-specific CD8(+) T cells during metastatic melanoma and reveal a new feature of dendritic cell vaccination in vivo.

PMID: 26942087 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2vH
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXru6X
via IFTTT

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Targeting TNF alpha as a novel strategy to enhance CD8(+) T cell-dependent immune response in melanoma?

Oncoimmunology. 2016;5(1):e1068495

Authors: Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B

Abstract
Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the accumulation of tumor-infiltrating CD8(+) T lymphocytes in experimental melanoma.

PMID: 26942089 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH078
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5FXO
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrsvX
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ImH
via IFTTT

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

The extent to which melanoma alters tissue-resident dendritic cell function correlates with tumorigenicity.

Oncoimmunology. 2016;5(1):e1069462

Authors: Hargadon KM

Abstract
We have shown that melanoma-derived factors alter the function of differentiated tissue-resident dendritic cells (DC) in a tumorigenicity-dependent manner. Soluble factors, including TGFβ1 and VEGF-A, contributed to dendritic cell dysfunction associated with a highly-aggressive melanoma and conferred a phenotype upon DC likely to favor immune escape and tumor outgrowth.

PMID: 26942090 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnj
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXru6R
via IFTTT

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Oncoimmunology. 2016;5(1):e1104448

Authors: Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N

Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the PDCD1 promoter. These PD-1(neg) clones were of lower avidity than their PD-1(pos) counterparts, suggesting that high-affinity-specific T cell clones unable to express PD-1 are not or rarely present in peripheral blood, as they are probably eliminated by negative selection, due to their high reactivity. We also documented the existence of such PD-1(neg) T cell clones in melanoma tumor-infiltrating lymphocytes (TIL), which also exhibited a lower functional avidity than PD-1(pos) TIL clones. This clearly shows that PD-1 expression identifies antigen-specific T cell clonotypes of high functional avidity. Finally, we demonstrated that PD-1 blockade during the in vitro selection process of Melan-A-specific T cells favored the amplification of higher avidity T cell clonotypes. This preferential amplification of high-avidity memory T cells upon PD-1 blockade resonates with the expansion of reactive T cells, including neo-antigen-specific T cells observed in anti-PD-1-treated patients. This feature should also be a useful biomarker of clinical efficiency, while providing new insights for adoptive transfer treatments.

PMID: 26942093 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH07k
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21P0jQz
via IFTTT

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Oncoimmunology. 2016;5(1):e1104448

Authors: Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N

Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the PDCD1 promoter. These PD-1(neg) clones were of lower avidity than their PD-1(pos) counterparts, suggesting that high-affinity-specific T cell clones unable to express PD-1 are not or rarely present in peripheral blood, as they are probably eliminated by negative selection, due to their high reactivity. We also documented the existence of such PD-1(neg) T cell clones in melanoma tumor-infiltrating lymphocytes (TIL), which also exhibited a lower functional avidity than PD-1(pos) TIL clones. This clearly shows that PD-1 expression identifies antigen-specific T cell clonotypes of high functional avidity. Finally, we demonstrated that PD-1 blockade during the in vitro selection process of Melan-A-specific T cells favored the amplification of higher avidity T cell clonotypes. This preferential amplification of high-avidity memory T cells upon PD-1 blockade resonates with the expansion of reactive T cells, including neo-antigen-specific T cells observed in anti-PD-1-treated patients. This feature should also be a useful biomarker of clinical efficiency, while providing new insights for adoptive transfer treatments.

PMID: 26942093 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH07k
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5ImB
via IFTTT

Doubling the blockade for melanoma immunotherapy.

Doubling the blockade for melanoma immunotherapy.

Oncoimmunology. 2016;5(1):e1106127

Authors: Galluzzi L, Eggermont A, Kroemer G

PMID: 26942094 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/21PZqnz
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrsvR
via IFTTT

First oncolytic virus approved for melanoma immunotherapy.

First oncolytic virus approved for melanoma immunotherapy.

Oncoimmunology. 2016;5(1):e1115641

Authors: Pol J, Kroemer G, Galluzzi L

Abstract
On 2015, October 27th, the US Food and Drug Administration (FDA) has officially approved talimogene laherparepvec (T-VEC, also known as OncoVEX(GM-CSF)) for use in melanoma patients with injectable but non-resectable lesions in the skin and lymph nodes. T-VEC (which is commercialized by Amgen, Inc. under the name of Imlygic®) becomes therefore the first oncolytic virus approved for cancer therapy in the US.

PMID: 26942095 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH2Mc
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/21S5FHh
via IFTTT

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

PD-1 expression conditions T cell avidity within an antigen-specific repertoire.

Oncoimmunology. 2016;5(1):e1104448

Authors: Simon S, Vignard V, Florenceau L, Dreno B, Khammari A, Lang F, Labarriere N

Abstract
Despite its negative regulatory role on tumor-specific T cells, Programmed cell death 1 (PD-1) is also a marker of activated tumor-infiltrating T cells. In cancer, PD-1 blockade partially reverses T cell dysfunction allowing the amplification of tumor reactive T cells. Here, we investigated the role of PD-1 signaling on effector/memory human T cells specific for shared melanoma antigens, derived from blood. We documented for the first time the existence of melanoma-specific T cell clones unable to express PD-1. This stable feature was due to the persistent methylation of the PDCD1 promoter. These PD-1(neg) clones were of lower avidity than their PD-1(pos) counterparts, suggesting that high-affinity-specific T cell clones unable to express PD-1 are not or rarely present in peripheral blood, as they are probably eliminated by negative selection, due to their high reactivity. We also documented the existence of such PD-1(neg) T cell clones in melanoma tumor-infiltrating lymphocytes (TIL), which also exhibited a lower functional avidity than PD-1(pos) TIL clones. This clearly shows that PD-1 expression identifies antigen-specific T cell clonotypes of high functional avidity. Finally, we demonstrated that PD-1 blockade during the in vitro selection process of Melan-A-specific T cells favored the amplification of higher avidity T cell clonotypes. This preferential amplification of high-avidity memory T cells upon PD-1 blockade resonates with the expansion of reactive T cells, including neo-antigen-specific T cells observed in anti-PD-1-treated patients. This feature should also be a useful biomarker of clinical efficiency, while providing new insights for adoptive transfer treatments.

PMID: 26942093 [PubMed - as supplied by publisher]

from melanoma2 via als.fakia on Inoreader http://ift.tt/1QxH07k
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TXrtQz
via IFTTT

Intraosseous schwannoma localized in the anterior mandible with multilocular radiolucency: A case report

Publication date: Available online 5 March 2016
Source:Oral Science International
Author(s): Yasuhiro Kawasaki, Hironobu Kobashi, Syouichirou Ishii, Noboru Yakushiji
Intraosseous schwannoma in the oral and maxillofacial regions is rare. It arises most commonly in the posterior region of the mandible due to the presence of the inferior alveolar nerve. There have been only seven reported cases of intraosseous schwannoma localized in the anterior region of the mandible, all of which involved unilocular radiolucency. In this study, we report the rare case of an intraosseous schwannoma localized in the anterior mandible with multilocular radiolucency. The radiographic and clinical features of this case may be helpful for providing a correct diagnosis and treatment in the future.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1TiyZ8s
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cOWq
via IFTTT

Comparison of Reconstruction Algorithms for Decreasing the Exposure Dose During Digital Tomosynthesis for Arthroplasty: a Phantom Study

Abstract

To explore the possibility of decreasing the radiation dose during digital tomosynthesis (DT) for arthroplasty, we compared the image qualities of several reconstruction algorithms, such as filtered back projection (FBP) and two iterative reconstruction (IR), methods maximum likelihood expectation maximization (MLEM) and the simultaneous iterative reconstruction technique (SIRT) under different radiation doses. The three algorithms were implemented using a DT system and experimentally evaluated by contrast-to-noise ratio (CNR), artifact spread function (ASF), and power spectrum measurements on a prosthesis phantom. The CNR and ASF data were statistically analyzed by a one-way analysis of variance. The effectiveness of each technique for enhancing the visibility of the prosthesis phantom was quantified by the CNR (reference dose vs. 20 % reduced dose in FBP, P = 0.62; reference vs. 37 % reduced dose in FBP, P = 0.16; reference vs. 55 % reduced dose in FBP, P < 0.05; reference vs. 20 % reduced dose in IR, P = 0.92; reference vs. 37 % reduced dose in IR, P = 0.40; reference vs. 55 % reduced dose in IR, P < 0.05) and ASF (reference dose vs. 20 % reduced dose in FBP, P = 0.25; reference vs. 37 and 55 % reduced dose in FBP, P < 0.05; reference vs. 20 % reduced dose in IR, P = 0.16; reference vs. 37 and 55 % reduced dose in IR, P < 0.05). The power spectra under the reference and reduced doses are equivalent. In this phantom study, the radiation dose of the reference dose could be decreased by 20 % with FBP and IR for consideration of common factors.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/21RU8rA
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1noPdyH
via IFTTT

Patient with chronic renal failure undergoing surgery.

Purpose of review: Chronic kidney disease (CKD) is an increasing health problem worldwide and is associated with a number of clinical challenges. In this paper, we review recent studies that deal with strategies for the management of patients with CKD undergoing surgery. Recent findings: Effective strategies for nephroprotection are crucial for the handling of patients with CKD in the perioperative setting to prevent complications and to avoid the progression of CKD. Due to the lack of perioperative studies with CKD patients there are only level 2 recommendations. First of all, this requires the identification of CKD patients through risk assessment and preoperative laboratory tests. In this regard, biomarkers, such as cystatin C may facilitate the detection of chronically impaired renal function. Secondly, particular attention should be paid to the maintenance of hemodynamic stability, including an adequate blood pressure and cardiac index and the preservation of intravascular volume. There is clear evidence that an unimpaired renal perfusion, guaranteed through hemodynamic stability, and an undisturbed fluid balance both reduce the incidence of acute kidney injury (AKI) and consequently the further deterioration of renal function. Thirdly, several studies demonstrate that tight glycemic control is associated with less renal impairment and better survival for patients with CKD. Lastly, the highest priority for the patient with CKD should be assigned to the prevention of AKI, which is an action of proven efficacy. Summary: Identification and risk stratification is crucial for the perioperative management of patients with CKD. To improve clinical outcomes, nonemergent procedures should be postponed, renal function optimized, nephrotoxic drugs avoided, and AKI prevented. Copyright (C) 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1QC9KIC
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cNld
via IFTTT

Amniotic fluid embolism: update and review.

Purpose of review: This article reviews our current understanding of amniotic fluid embolism (AFE), specifically the pathogenesis, treatment strategies, potential diagnostic tests and future therapeutic interventions for AFE. Recent findings: The incidence and case mortality of AFE varies widely because of heterogeneous diagnostic criteria and varying reporting mechanisms across the world. Amniotic fluid embolism is thought to be caused by abnormal activation of immunologic mechanisms following entry of fetal antigens into maternal circulation. Mast cell degranulation and complement activation may play a role in this anaphylactoid or systemic inflammatory response syndrome. Development of serum biomarkers and immune-histochemical staining techniques to aid diagnosis and develop treatments are under development and evaluation. Treatment of AFE is supportive and directed at treating cardiovascular, pulmonary, and coagulation derangements. Treatment for coagulopathy (fresh frozen plasma, cryoprecipitate/fibrinogen concentrate, and antifibrinolytics) should be initiated promptly. Recombinant factor VIIa may lead to increased mortality and should not routinely be used. C1 esterase inhibitors may be a potential therapeutic option. Summary: AFE is a devastating obstetric complication that requires early and aggressive intervention with optimal cardiopulmonary resuscitation, as well as hemorrhage and coagulopathy management. Biomarkers offer promise to aid the diagnosis of AFE, and immunomodulation may provide future therapeutic interventions to treat this lethal condition. Copyright (C) 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1pskRgn
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1noPdir
via IFTTT

Adverse events of postoperative thoracic epidural analgesia, a retrospective analysis of 7273 cases in a tertiary care teaching hospital.

BACKGROUND: Thoracic epidural analgesia is a well established technique for postoperative pain relief after major abdominal and thoracic surgery. Safety remains a major concern because of serious adverse events including epidural haematoma, abscess and permanent neurological deficit. OBJECTIVE: The aim of this study was to evaluate the incidence and the long-term outcome of serious adverse events associated with thoracic epidural analgesia. DESIGN: Retrospective cohort study. SETTING: The study was conducted at a single institution, a tertiary care teaching hospital. Data were collected over a 10-year period from 2003 until 2012. PATIENTS: Data from 7430 patients were prospectively entered into a standardised acute pain service database. A total of 7273 study participants met the inclusion criteria and were included in the final analyses. The inclusion criteria involved surgical patients receiving a postoperative thoracic epidural analgesia catheter treatment for pain control. Exclusion criteria were defined as obstetric, non-surgical, non-epidural analgesia patients and epidural analgesia catheters that had not been placed by an anaesthesiologist. MAIN OUTCOME MEASURES: The database was queried for serious adverse events which were defined as spinal or epidural haemorrhage; spinal or epidural abscess; permanent neurological deficits; cardiac arrest; death and incomplete removal of the epidural analgesia catheter. Patients' charts were comprehensively reviewed in case of a major adverse event. Patients with an unclear outcome received a mailed questionnaire or were contacted by telephone to determine long-term sequelae. RESULTS: Seven serious adverse events were identified: epidural abscess [n = 1; incidence 1 : 7273 (0.014%, 95% confidence interval, CI, 0 to 0.08%)], persistent neurological damage [n = 1; incidence 1 : 7273 (0.014%, 95% CI, 0 to 0.08%)], cardiac arrest [n = 1; incidence 1 : 7273 (0.014%, 95% CI, 0 to 0.08%)] and catheter breakage leaving a catheter fragment in situ [n = 4; incidence 1 : 1818 (0.055%, 95% CI, 0.01 to 0.14%)]. Apart from the one patient with persistent neurologic deficit, the patients with serious adverse events associated with thoracic epidural analgesia in our cohort suffered no long-term consequences. CONCLUSION: In our single-centre study of thoracic epidural analgesia, serious adverse events occurred in 0.1% cases (1 : 1000), whereas long-term outcome was compromised in 0.014% (1.4 : 10 000) which is similar to the serious adverse event rates and outcomes reported in the current literature. TRIAL REGISTRATION: n.a. (C) 2016 European Society of Anaesthesiology

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1R0tife
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cOWb
via IFTTT

Reply to: postoperative shoulder pain after laparoscopic hysterectomy with deep neuromuscular blockade and low-pressure pneumoperitoneum.

No abstract available

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1Yh8ek8
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1noPfXk
via IFTTT

Intraoperative hypotension is associated with myocardial damage in noncardiac surgery: An observational study.

BACKGROUND: Perioperative myocardial damage and infarction (MI) is associated with increased mortality and other postoperative complications. OBJECTIVES: To assess the incidence of perioperative myocardial damage in patients undergoing major elective noncardiac surgery, to elucidate any association with postoperative MI and mortality and to estimate the impact of preoperative risk factors and intraoperative hypotension. DESIGN: Observational cohort study. SETTING: Karolinska University Hospital, Stockholm, Sweden, from October 2012 to May 2013. PATIENTS: In this single-centre study, all adult patients undergoing major elective noncardiac surgery who were scheduled for an overnight admission to the postoperative unit were included. Patients undergoing phaeochromocytoma surgery were excluded. Preoperative risk factors (co-morbidities), intraoperative events (hypotension defined as a 50% decrease in SBP relative to each patient's baseline and lasting >5 min) and postoperative data were collected from medical records. Levels of high-sensitivity cardiac troponin T (hs-cTnT) were measured on postoperative day 1. Myocardial damage was defined as an increase in the hs-cTnT value above 14 ng l-1. A cardiologist reviewed all cases of MI occurring within 30 days after surgery. MAIN OUTCOME MEASURES: Myocardial damage, MI and mortality within 30 days after surgery. RESULTS: Of the final cohort of 300 patients, 90 (30%) had myocardial damage on postoperative day 1 and 15 (5%) developed postoperative MI within 30 days. Multivariate logistic regression analysis demonstrated that an intraoperative reduction in SBP more than 50% from baseline lasting more than 5 min was an independent predictor of postoperative hs-cTnT elevation (odds ratio, 4.4; 95% confidence interval, 1.8 to 11.1). CONCLUSIONS: In a cohort of 300 patients undergoing major elective noncardiac surgery, there was a high incidence of myocardial damage and an association between an intraoperative reduction in SBP more than 50% from baseline lasting more than 5 min and myocardial damage. (C) 2016 European Society of Anaesthesiology

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1R0tgDY
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cOFV
via IFTTT

Satisfaction and safety using dexmedetomidine or propofol sedation during endoscopic oesophageal procedures: A randomised controlled trial.

BACKGROUND: Dexmedetomidine possesses anxiolytic and hypnotic properties without respiratory side-effects, making it theoretically an ideal sedative agent for endoscopic procedures. OBJECTIVE: We aimed to compare satisfaction and safety among outpatients receiving sedation with dexmedetomidine or propofol for endoscopic oesophageal procedures. DESIGN: A randomised controlled study. SETTING: Endoscopic intervention suite at the Academic Medical Centre in Amsterdam, Netherlands. PARTICIPANTS: Patients aged at least 18 years, and American Society of Anesthesiologists' physical status 1 to 3. INTERVENTION: Total 63 patients were randomised to receive either dexmedetomidine (D) or propofol (P). Pain was treated with alfentanil in both groups. MAIN OUTCOME MEASURES: The primary outcomes were patients' and endoscopists' satisfaction levels measured by validated questionnaires (1 = very dissatisfied; 7 = highly satisfied). A secondary outcome was safety, determined by blood pressure, heart rate and oxygen saturation during and after the procedure, and respiratory rate and noninvasive cardiac output during the procedure. RESULTS: Satisfaction of patients [median (IQR); group D, 5.0 (3.75 to 5.75) vs. group P, 6.25 (5.3 to 6.5)] and satisfaction of gastroenterologists [group D, 5.0 (4.4 to 5.8) vs. group P, 6.0 (5.4 to 6.0)] were lower in group D (both P

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1Yh8e3B
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1noPdic
via IFTTT

Anaesthesia for orphan disease: Rocuronium and sugammadex in the anaesthetic management of a parturient with Becker’s myotonia congenita.

No abstract available

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1R0tgnF
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cOFT
via IFTTT

Transcutaneous vocal cord ultrasonography after oral and maxillofacial surgery requiring intermaxillary fixation: A technical report.

No abstract available

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader http://ift.tt/1TXeEFF
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1noPfH4
via IFTTT

Patient with chronic renal failure undergoing surgery.

Purpose of review: Chronic kidney disease (CKD) is an increasing health problem worldwide and is associated with a number of clinical challenges. In this paper, we review recent studies that deal with strategies for the management of patients with CKD undergoing surgery. Recent findings: Effective strategies for nephroprotection are crucial for the handling of patients with CKD in the perioperative setting to prevent complications and to avoid the progression of CKD. Due to the lack of perioperative studies with CKD patients there are only level 2 recommendations. First of all, this requires the identification of CKD patients through risk assessment and preoperative laboratory tests. In this regard, biomarkers, such as cystatin C may facilitate the detection of chronically impaired renal function. Secondly, particular attention should be paid to the maintenance of hemodynamic stability, including an adequate blood pressure and cardiac index and the preservation of intravascular volume. There is clear evidence that an unimpaired renal perfusion, guaranteed through hemodynamic stability, and an undisturbed fluid balance both reduce the incidence of acute kidney injury (AKI) and consequently the further deterioration of renal function. Thirdly, several studies demonstrate that tight glycemic control is associated with less renal impairment and better survival for patients with CKD. Lastly, the highest priority for the patient with CKD should be assigned to the prevention of AKI, which is an action of proven efficacy. Summary: Identification and risk stratification is crucial for the perioperative management of patients with CKD. To improve clinical outcomes, nonemergent procedures should be postponed, renal function optimized, nephrotoxic drugs avoided, and AKI prevented. Copyright (C) 2016 YEAR Wolters Kluwer Health, Inc. All rights reserved.

from Anaesthesiology via xlomafota13 on Inoreader http://ift.tt/1QC9KIC
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1p8cN4P
via IFTTT

People’s Military Surgeon, Year 2016, Issue 02 -New Issue Alert.

From: order@email.oriprobe.com

Date: March 06, 2016 at 08:08AM

New Issue TOC Alert Dear Valued Customer, We are pleased to deliver your requested table of contents alert for People's Military Surgeon. Year 2016 Issue 02 is now available on CAOD. In this issue: PEOPLE'S MILITARY MEDICAL PRESS (人民軍醫出版社) …… page:105 tian jin gang te bie zhong da huo zai bao zha shi gu yi xue jiu yuan de zuo fa yu si kao (天津港特别重大火灾爆炸事故医学救援的做法与思考) WANG Jun, CAO Min, XIE Ming, DONG Junjie …… page:111-113 zhong yao ti xing (重要提醒) BEN Kanbianjibu …… page:113 zhuang jia bing mou bu guan bing jian kang su yang zhuang kuang diao cha yu fen xi (装甲兵某部官兵健康素养状况调查与分析) ZHOU Sheng, ZHANG Yan, QIAN Zuo, ZHANG Buzhen …… page:114-115+121 ya jia lan he ji zhi liao guan bing zhong du gang zuo yan liao xiao guan cha (亚甲蓝合剂治疗官兵重度肛窦炎疗效观察) YUAN Ting, WANG Zhaowei, SHAO Mingyong, WANG Junfeng …… page:116-117 mou yi yuan jun ren huan zhe xin shen xing pi fu bing diao cha fen xi (某医院军人患者心身性皮肤病调查分析) LIU Zhenfeng, LIU Zhaoqiang, DENG Yang …… page:118-119 bu shi jun bing wu zhen wei shang hu xi dao gan ran 1 li (布氏菌病误诊为上呼吸道感染1例) YANG Jinbo, SUN Li, CAO Lin, NIE Ming, ZHU Guizhong …… page:119 mou bu xin bing fu jian gao xue niao suan ji gao gu bing zhuan an mei qing kuang diao cha (某部新兵复检高血尿酸及高谷丙转氨酶情况调查) SONG Shiling, FU Juzuo, GU Jingang …… page:120-121 nv jun ren jun shi xun lian shang ying xiang yin su fen xi yu dui ce (女军人军事训练伤影响因素分析与对策) XU Ya, SUN Jinhai, WANG Xinwei, LUO Yibin …… page:122-124 ji dong bu dui fang zhi deng ge re de nan dian yu dui ce (机动部队防治登革热的难点与对策) ZHANG Lihong, SHI Zuo, CHEN Jie, MA Shiwu …… page:125-127 zhu min mou bu yi qi gou duan luo xuan ti bing yi qing de chu zhi yu si kao (驻闽某部一起钩端螺旋体病疫情的处置与思考) MA Weimin, WANG Shaoyang, LIU Haizhou …… page:128-129 zou guan lian he zhen ci zhi liao ji ceng guan bing yao ji lao sun 297 li (走罐联合针刺治疗基层官兵腰肌劳损297例) GUO Yanjun, GUO Dingxuan, GUO Qiang …… page:129 ri yi hua wu yi dong yun shu yi liao bao zhang zu zhi guan li shi jian (日遗化武移动运输医疗保障组织管理实践) SU Jianbin, SHI Wei, ZHANG Huiyang, YANG Xinglong, LI Yanbo, ZHANG Hong, LIU Sugang …… page:130-131+146 wei qin zhi hui mo ni xun lian xi tong she ji yu kai fa (卫勤指挥模拟训练系统设计与开发) MA Jianwei, LI Jianjie, YU Zuo, HUANG Chaozuo …… page:132-133 mei hai jun yi yuan chuan gong neng ding wei yu qi shi (美海军医院船功能定位与启示) LI Dawei, YANG Xiaobin, SUN Tao …… page:134-135 jun shi si chou zhi lu zhan lue wen ming hu xin yu lv yue yan jiu ( xia ) (军事丝绸之路战略文明互信与履约研究(下)) CUI Zuozuo, WANG Songjun, DIAO Jun, XU Shunxiong, LUO Changshuang, LIU Hubo …… page:136-137+146 guo wai hai jun liang qi jian ting yi liao she shi jian jie (国外海军两栖舰艇医疗设施简介) LU Zuozuo, CHEN Bohua, LI Xuxia, YAO Yongjie, WANG Min …… page:138-139 yuan hang dui nv jian yuan nei fen mi he yue jing deng qing kuang ying xiang de guan cha (远航对女舰员内分泌和月经等情况影响的观察) WANG Wei …… page:140-141+152 xin sheng er que yang que xue xing nao bing fa bing ji yu hou ying xiang yin su fen xi (新生儿缺氧缺血性脑病发病及预后影响因素分析) HUANG Weiqing, PENG Xiaoming, YAN Weiqun, XIAO Yong, ZHANG Fan …… page:142-144 13c- niao su hu qi shi yan yong yu jian kang ti jian you men luo gan jun jian ce jia zhi yan jiu (13C-尿素呼气试验用于健康体检幽门螺杆菌检测价值研究) NIU Xiaoyu, ZHANG Mei, HUANG Hui, NIU Yuchun …… page:145-146 jian kang feng xian ping gu dui ge xing hua jian kang gan yu de jia zhi yan jiu (健康风险评估对个性化健康干预的价值研究) WEI Xinju, HAO Wenjian, CAO Qin …… page:147-148 ren gong niu huang jia xiao zuo jiao nang zhi bian tai fan ying 1 li (人工牛黄甲硝唑胶囊致变态反应1例) XIE Faxian …… page:148 fu qiang jing yu kai fu shou shu zhi liao pen qiang nong zhong xiao guo dui bi guan cha (腹腔镜与开腹手术治疗盆腔脓肿效果对比观察) ZHOU Xiangdong, LIU Lu, JIANG Bo, TONG Ying …… page:149-150 you ye xia xiao qie kou yu xiong gu zheng zhong qie kou zhi liao er tong xian tian xing xin zang bing xiao guo dui bi guan cha (右腋下小切口与胸骨正中切口治疗儿童先天性心脏病效果对比观察) ZHOU Entao, JIN Xidong, LIU Dazhi, YANG Wenju, WANG Xiandong …… page:151-152 san zhong fang fa yong yu gao ling nan xing jie chang jing jian cha qian chang dao zhun bei xiao guo guan cha (三种方法用于高龄男性结肠镜检查前肠道准备效果观察) WANG Ji, HU Zhi, FU Zuozuo, ZHU Zheyu, FU Siqi, LI Yong, WANG Jin …… page:153-155 chou yang guan jie qiang nei zhu she zhi liao xi gu guan jie yan liao xiao guan cha (臭氧关节腔内注射治疗膝骨关节炎疗效观察) WANG Hongfei, XIA Dongcai …… page:156-157 gan xiu suo jia qiang yao pin guan li de zuo fa (干休所加强药品管理的做法) XIA Xianbo, BAI Chuanlin …… page:157 chang gui jia shuang shui ping zheng ya tong qi zhi liao copd he bing osahs xiao guo guan cha (常规加双水平正压通气治疗COPD合并OSAHS效果观察) ZHAO Xiaoyan, LIU Jianfeng, YAN Zhigang, SU Jinlin …… page:158-160 gao ling huan zhe xin xue guan ji bing wei xian yin su yu chao min c fan ying dan bai de xiang guan xing yan jiu (高龄患者心血管疾病危险因素与超敏C反应蛋白的相关性研究) WANG Chunhong, ZHOU Zuo, WANG Lanxiang, WANG Lian, LI Chunlin, LI Huijuan …… page:161-163 yi dao su zhong du fen mi bu zu ban bu tong cheng du yi dao su di kang de 2 xing tang niao bing dui bi guan cha (胰岛素重度分泌不足伴不同程度胰岛素抵抗的2型糖尿病对比观察) YANG Zhengguo, ZUO Xinai, WANG Shuang, YANG Bo, ZHENG Jinliang, JIA Wei, CAI Xinli, ZHAO Jinjuan, LIU Lihui, ZHANG Ying …… page:164-166 ning mi tai lian he chang gui yao wu zhi liao iga shen bing xiao guo guan cha (宁泌泰联合常规药物治疗IgA肾病效果观察) LIU Qianhong, HOU Liang, YANG Xudong …… page:167-168 bu yang huan wu tang he zuo yao san fu zhu zhi liao zu zhong hou pi lao xiao guo guan cha (补阳还五汤合逍遥散辅助治疗卒中后疲劳效果观察) LIANG Yahui, GONG Weijun, SU Ying, LI Chengjia …… page:169-170 zhen ci lian he zhong yao guan chang zhi liao wei zhong zheng huan zhe wei chang gong neng zhang ai xiao guo guan cha (针刺联合中药灌肠治疗危重症患者胃肠功能障碍效果观察) HE Shuyin …… page:171-173 xin li gan yu dui zhuo kou zong he zheng huan zhe jiao lv ji yi yu qing xu ying xiang de guan cha (心理干预对灼口综合征患者焦虑及抑郁情绪影响的观察) SHAO Lixin, CHEN Chun, HUANG Minhua …… page:174-175 zhu nan su dan wei he er ji yi yuan huan zhe yan ke ji bing pu yu yao pin shi yong qing kuang diao cha (驻南苏丹维和二级医院患者眼科疾病谱与药品使用情况调查) TIAN Fang, LIU Dawei, WANG Zuo …… page:176-178 ren min jun yi za zhi ying xiang yin zi tu po 0.8 da guan (《人民军医》杂志"影响因子"突破"0.8"大关) BEN Kanbianjibu …… page:178 xi pa yi gu zuo ye lian he ya zhou ji chu zhi liao dui man xing ya zhou yan de liao xiao guan cha (西帕依固龈液联合牙周基础治疗对慢性牙周炎的疗效观察) ZHOU Ming, LIN Songshan, WANG Feng, ZHAO Yingzuo, GU Jing, ZHOU Qiuping, CHEN Zuo …… page:179-180 xin fa ta ting zhi ke su 1 li (辛伐他汀致咳嗽1例) QIN Ping, CAO Ping …… page:180 liang zhong hui bo shi jian zeng qiang 3d-stir bi cong shen jing cheng xiang xiao guo bi jiao (两种回波时间增强3D-STIR臂丛神经成像效果比较) HUANG Minhua, WANG Qingjun, GUO Yong, SHAO Lixin, ZHANG Jing …… page:181-182 dan zong guan qie kai qu shi yi qi feng he 31 li fen xi (胆总管切开取石一期缝合31例分析) GUO Hongrong, HOU Yuefeng, XU Zhonghua, SHI Chi …… page:183-184 nei jing xia gao pin dian zhi liao duan di wei da xi rou 42 li fen xi (内镜下高频电治疗短蒂胃大息肉42例分析) LI Yingxin, ZU Qingyu, YANG Guochang, CHEN Limin …… page:185-186 feng mian ren wu jian jie (封面人物简介) …… page:186 nan yu he chuang mian 49 li wu li zhi liao fen xi (难愈合创面49例物理治疗分析) LI Zuo, ZHANG Zuo, HAN Huanping, ZHANG Hui, GAO Jizhen, TIAN Youliang …… page:187-188 zuo dong mai chuan ci zhi qiao zhi yan zhong mi zou shen jing fan she 1 li (桡动脉穿刺置鞘致严重迷走神经反射1例) MO Xingang, CHEN Jinliang, JIA Baomin, ZHANG Jian, ZHANG Jing, GUO Zuozuo …… page:188 zhen ci lian he xue wei zhu she zhi liao tang niao bing 60 li fen xi (针刺联合穴位注射治疗糖尿病60例分析) XU Ning, HE Yeqian, HUANG Genshan, ZUO Weidong, WANG Hua, TAO Ye, YANG Liangcheng, HAN Ding …… page:189-190 jie chuang wu zhen wei qiu zhen xing zuo ma zhen 1 li (疥疮误诊为丘疹性荨麻疹1例) DONG Qibin, MA Zuo …… page:190 zhong yao zhi liao fu ke shu hou fei gan ran xing fa re 77 li (中药治疗妇科术后非感染性发热77例) HUANG Heling, LIU Liping …… page:191-192 fei na xiong an zhi pi fu zuo yang 1 li (非那雄胺致皮肤瘙痒1例) TANG Yunke, ZHANG Juan …… page:192 cai se duo pu le chao sheng zhen duan zhi fang gan zhong di hui sheng bing zao 91 li fen xi (彩色多普勒超声诊断脂肪肝中低回声病灶91例分析) CAO Guohui, DAI Weichuan, RAN Qichuan, GUO Zuoli …… page:193-194 ji xing chuang shang xing ning xue gong neng zhang ai yan jiu jin zhan (急性创伤性凝血功能障碍研究进展) MEN Zuolei, WANG Wei …… page:195-197 dian ji shang zhi xin bo hu xi zhou ting 20min qiang jiu cheng gong 1 li (电击伤致心搏呼吸骤停20min抢救成功1例) ZHANG Lei, WANG Lei, LI Yongjun …… page:197 xin xue guan ji bing shi jiao gan shen jing net biao da ji gong neng bian hua yan jiu jin zhan (心血管疾病时交感神经NET表达及功能变化研究进展) QI Yue, TIAN Zejun, LI He, FANG Jiaxiong …… page:198-200 zhu wang mo xia qiang chu xue zhong cheng yao de he li ying yong (蛛网膜下腔出血中成药的合理应用) ZHANG Chenzuo, PANG Haolong, GONG Lianbing …… page:201-202 ji ceng yi shi zai ji bing zhen zhi zhong ying zhong shi cha ti (基层医师在疾病诊治中应重视查体) LI Zhirun …… page:202 ren shen qi mu ti sheng li bian hua ji bao jian (妊娠期母体生理变化及保健) GUAN Huai, SHANG Lixin …… page:203-205 yin jing zhong xian nang zhong 1 li (阴茎中线囊肿1例) CHENG Zuo, tan , TAN Zongcai, WEN Jun …… page:205 yun nan lu dian di zhen zai hai te dian yu yi liao jiu yuan shi jian (云南鲁甸地震灾害特点与医疗救援实践) LIU Li, ZHOU Xiaobin, YUAN Zuo, BAO Caiqin, CAI Changxia, LIU Qinghua …… page:206-207 gao hao xun lian shang fang hu zhi shi xuan jiao de tan tao (搞好训练伤防护知识宣教的探讨) CHEN Wenmin, WU Gaoxian, YANG Yunjian, WEI Lei, DI Zhenyan …… page:208-209 jia qiang ji ceng yao pin guan li gong zuo de zuo fa (加强基层药品管理工作的做法) ZHU Ping, ZHANG Huihong, TANG Xinhua …… page:210 fu mo hou ping hua ji rou liu qin fan xia qiang jing mai 1 li (腹膜后平滑肌肉瘤侵犯下腔静脉1例) HUANG Cong, ZUO Dengwei, ZHAO Zuolin, LUO Junde …… page:211 ji xing yi xing gan yan he bing jie he xing nao nong zhong yan wu zhen zhi 1 li (急性乙型肝炎合并结核性脑脓肿延误诊治1例) BI Hongjun, WANG Daoming …… page:212 li zu yu ji ceng xu qiu zhi li yu gai ge chuang xin hui wang ren min jun yi za zhi wei bu dui fu wu zu ji (立足于基层需求 致力于改革创新——回望《人民军医》杂志为部队服务足迹) WANG Min, ZHANG Linping …… page:213 CAOD TOC Alerts Note Thank you for choosing CAOD Table of Contents (TOC) Alert Service. You are receiving this email because you have requested to receive information from CAOD as a registered user of our Table of Content Alert for journals. To manage your TOC Alerts, please click here. For all enquiries, problems or suggestions regarding this service, please contact info. China/Asia on Demand (CAOD) Customer Service

from Gmail
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1TiH0dr
via IFTTT

Chinese Journal of Cellular and Molecular Immunology, Year 2016, Issue 01 -New Issue Alert.

From: order@email.oriprobe.com

Date: March 06, 2016 at 08:08AM

New Issue TOC Alert Dear Valued Customer, We are pleased to deliver your requested table of contents alert for Chinese Journal of Cellular and Molecular Immunology. Year 2016 Issue 01 is now available on CAOD. In this issue: Domestication of suspension CHO cells and its application in the expression of anti-PSMA antibody (悬浮驯化CHO细胞并用于抗前列腺特异性膜抗原的抗体表达) WU Jieheng, HAN Donghui, WEI Ming, ZHENG Guoxu, JIAO Dian, XI Wenjin, YANG Angang, QIN Weijun, WEN Weihong, Department of Immunology, School of Basic Medicine, Xijing Hospital, Department of Urology, Xijing Hospital, Department of Urology, Tangdu Hospital, Fourth Military Medical University, Department of Immunology, School of Basic Medicine, Xijing Hospital, Xi'an 710032 …… page:1-4+9 Valsartan inhibits angiotensinⅡ-Notch signaling of mesangial cells induced by high glucose (缬沙坦抑制高糖刺激下系膜细胞血管紧张素Ⅱ-Notch通路) YUAN Qin, LYU Chuan, WU Can, LEI Sha, SHAO Ying, WANG Qiuyue, Department of Endocrinology, First Affiliated Hospital, China Medical University …… page:5-9 β-Glucan promotes the maturation and migration of bone marrow-derived dendritic cells (β葡聚糖促进小鼠骨髓来源的树突状细胞成熟并增强其迁移能力) XU Dongqin, ZHANG Xiaohang, WANG Yong, NING Yongling, DING Jun, QIAN Keqing, QI Chunjian, Medical Research Center, Changzhou Second People's Hospital, Nanjing Medical University …… page:10-14 Depressive effect of cigarette smoke extracts on dendritic cells inducing differentiation of CD4~+T cells into CD4~+CD25~+Foxp3~+Tregs (香烟烟雾提取物抑制树突状细胞诱导CD4~+T细胞分化为CD4~+CD25~+Foxp3~+调节性T细胞) LIANG Yi, ZHOU Guang, ZHANG Longju, LIU Jifeng, ZHONG Xiaoning, The Department of Respiratory Medicine, the First Affiliated Hospital of Guangxi Medical University …… page:15-19 Peripheral blood endothelial progenitor cells enhance the expressions of SDF-1 and MCP-1 of bone marrow stromal cells and promote their homing ability (外周血内皮祖细胞可增强骨髓间充质干细胞SDF-1和MCP-1的分泌并促进其归巢) WEI Hanxiao, LI Caixia, ZHAO Xian, YUAN Ruihong, DAI Xiaoming, LI Yisong, LIU Liu, Department of Plastic Surgery, First Affiliated Hospital, Kunming Medical University …… page:20-24 Stable expression of recombinant human podoplanin in Chinese hamster ovary(CHO) cells (重组人平足蛋白基因在中国仓鼠卵巢细胞的稳定表达) QU Le, ZHAO Xingpeng, FU Jianxin, XIA Lijun, DAI Lan, RUAN Changgeng, ZHAO Yiming, Jiangsu Institute of Hematology, Ministry of Health Key Laboratory of Thrombosis and Haemostasis, First Affiliated Hospital, Soochow University …… page:25-28+33 Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells (隐丹参酮下调U2OS骨肉瘤细胞血管内皮生长因子表达并抑制血管生成) XU Yameng, JI Quanbo, ZHANG Qiang, WANG Yan, Department of Traditional Chinese Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Department of Orthopaedics, 301 Hospital …… page:29-33 Keratin 18 phosphorylation increases autophagy of colorectal cancer HCT116 cells and enhanced its sensitivity to oxaliplatin (角蛋白18磷酸化增加结肠癌HCT116细胞自噬并提高其对奥沙利铂的敏感性) YAN Xiaodong, SHI Ying, KOU Buxin, ZHU Zhenyu, CHAI Jie, CHEN Dexi, GUO Hongliang, Department of General Surgery, Shandong Cancer Hospital, School of Medicine and Life Sciences, Shandong Academy of Medical Sciences, University of Jinan, Department of Infectious Diseases, Beijing Youan Hospital, Capital Medical University …… page:34-38+43 Adipose-derived stem cell transplantation inhibits the expression of Nogo-A in the perilesional cortex of rats with focal cerebral ischemia (脂肪干细胞移植抑制脑缺血大鼠梗死灶周围组织Nogo-A的表达) WANG Jiehua, LI Guoqian, Department of Neurology, First Affiliated Hospital of Quanzhou, Fujian Medical University …… page:39-43 miR-365 inhibits proliferation and promotes apoptosis of SOSP9607 osteosarcoma cells (miR-365抑制骨肉瘤细胞增殖并促进其凋亡) GAO Jinjian, ZHAO Pin, CHEN Xu, WANG We, LI Yufang, XI Wenjin, ZHANG Wei, HU Pingping, WANG Tao, SHAN Lequn, Department of Orthopaedics, Tangdu Hospital, Fourth Military Medical University, Department of Anesthesiology, Tangdu Hospital, Fourth Military Medical University, Department of Immunology, School of Basic Medicine, Fourth Military Medical University, Department of neurosurgery, Tangdu Hospital, Fourth Military Medical University, Department of Digestive Diseases, Navy General Hospital …… page:44-48 Expression of mannose-binding lectin associated protein 19(MAp19) in HeLa cells (甘露聚糖结合凝集素相关蛋白19(MAp19)在HeLa细胞的表达) LI Ting, LI Ping, JIA Tianjun, JIA Xiaohui, ZHAO Xia, CHENG Yongting, Research Institute of Pathogen Biology and Immunology, Key Laboratory of Clinical Diagnostics, Hebei North University …… page:49-53 Immunomodulatory effect of Huangqi glycoprotein on mice with experimental autoimmune encephalomyelitis (黄芪糖蛋白对实验性自身免疫性脑脊髓炎小鼠的免疫调节作用) ZHANG Peijun, GUO Minfang, XING Yanxia, YANG Debing, ZHANG Lihong, LI Yanhua, XUE Huiqing, XIAO Baoguo, MA Cungen, Institute of Brain Science, Shanxi Datong University, "2011"Collaborative Innovation Center, Research Center of Neurobiology, Shanxi University of Traditional Chinese Medicine, Institute of Neurology, Huashan Hospital, Fudan University …… page:54-58 Diphenylene iodonium and apocynin reduce the translocation and level of p47phox in PBMCs of premature infants to inhibit reactive oxygen species production (二苯基碘和夹竹桃麻素通过降低早产儿外周血单个核细胞p47phox位移与水平减少活性氧的产生) ZHANG Lingping, DONG Wenbin, LI Qingping, KANG Lan, ZHANG Lianyu, LU Youying, ZHAI Xuesong, The First Affiliated Hospital of Sichuan Medical University …… page:59-62 Macrophage phagocytosis enhanced by Tiaohengfang polysaccharides in vitro (调衡方多糖增强体外培养巨噬细胞的吞噬能力) ZHANG Hongfang, YU Penglong, ZHENG Yu, YU Dongbo, WU Fang, WANG Xisheng, HUAN Cheng, ZHANG Yimin, Shaanxi University of Traditional Chinese Medicine …… page:63-66 ji shang han sha men jun jian du zhu 1009 spic crp de bao hu xiao li ping jia (鸡伤寒沙门菌减毒株1009ΔspiCΔcrp的保护效力评价) CHENG Bing, YANG Meizuo, YIN Junlei, KANG Xilong, HU Maozhi, PAN Zhiming, JIAO Xinan …… page:67-70 mi nuo huan su yi zhi zhu wang mo xia qiang chu xue da shu nao zu zhi xiao jiao zhi xi bao / ju shi xi bao huo hua gai shan xue guan bing bian (米诺环素抑制蛛网膜下腔出血大鼠脑组织小胶质细胞/巨噬细胞活化改善血管病变) XIU Binhua, liu , XING Guoxiang, ZHENG Gang, ZOU Zhihao, ZUO Zhiqiang …… page:71-74 xia diao han zhi wu tong yuan jie gou yu he huan zhi jie gou yu fan su yang dan bai 1(uhrf1) de shui ping ke yi zhi shen ai 769-p xi bao zeng zhi bing cu jin qi diao wang (下调含植物同源结构域和环指结构域泛素样蛋白1(UHRF1)的水平可抑制肾癌769-P细胞增殖并促进其凋亡) JIAO Dian, ZHENG Jia, WEI Ming, ZHENG Guoxu, XI Wenjin, QIN Weijun, YANG Angang, WANG He, WEN Weihong …… page:75-78 man xing jian xie di yang da shu fei pao shang pi xi bao ccaat/ zeng qiang zi jie he dan bai tong yuan dan bai (chop) biao da zeng qiang (慢性间歇低氧大鼠肺泡上皮细胞CCAAT/增强子结合蛋白同源蛋白(CHOP)表达增强) ZHANG Jiabin, ZHANG Panpan, KOU Yule, WANG Hongyang, WANG Ling, ZHANG Min, YU Jiangtao, WANG Yazuo …… page:79-80+83 ke you dao xi bao diao wang de fkbp12/caspase-9 man bing du zai ti de gou jian yu ying yong (可诱导细胞凋亡的FKBP12/caspase-9慢病毒载体的构建与应用) LEI Yanjie, SUN Xiangdong, WANG Chunrong, ZHU Wuling, HAN Shuangyin …… page:81-83 High expression of cyclin D1 is correlated with the expression of estrogen receptor and good prognosis in breast cancer (细胞周期蛋白D1的高表达与雌激素受体表达及乳腺癌患者良好预后相关) YANG Chengcheng, NAN Kejun, ZHANG Yamin, CHEN Yimeng, QIN Sida, Department of Oncology, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Department of Thoracic Surgery, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University …… page:84-87 Increased IL-1 and IL-6 expressions are negatively correlated with modified Japanese Orthopedic Association(mJOA) scores of discogenic low back pain (IL-1和IL-6的表达增强且与盘源性下腰痛改良日本骨科学会(mJOA)评分负相关) YANG Jian, KANG Jianping, FENG Daxiong, WANG Song, YANG Han, Department of Spine Surgery, Affiliated Hospital, Luzhou Medical College …… page:88-91 Detection of TSC1/TSC2 gene mutation for rapid diagnosis of tuberous sclerosis complex by high-throughput sequencing technology (结节性硬化症TSC1/TSC2基因突变的高通量测序快速诊断) HUANG Changyan, Clinical laboratory, Ganzhou Municipal Hospital …… page:92-95 ren zi gong nei mo he zi gong nei mo yi wei zheng huan zhe zai wei nei mo xi bao pei yang ji xing tai (人子宫内膜和子宫内膜异位症患者在位内膜细胞培养及形态) ZHANG Tianzuo, CONG Huifang …… page:96-98+102 ji xing bai xue bing huan zhe xue qing th1 xi bao he th2 xi bao bu fen xiang guan xi bao yin zi shui ping bian hua (急性白血病患者血清Th1细胞和Th2细胞部分相关细胞因子水平变化) DONG Zuo, JIANG Yaxian, ZHANG Qin, DIAN Zijin, SONG Jianxin, YANG Zuo, OU Yanghongmei …… page:99-102 cfan ying dan bai dan ke long kang ti de zhi bei ji jia xin elisa de jian li he ying yong (C反应蛋白单克隆抗体的制备及夹心ELISA的建立和应用) CHEN Yazuo, SONG Chaojun, LI Zuo, LI Na, DONG Zuo, TIAN Ying, JIN Boquan, MA Ying …… page:103-105 Preparation and application of monoclonal antibody against human vascular endothelial cadherin 5 (人血管内皮钙黏蛋白5单克隆抗体的制备及应用) DING Jie, HE Yang, YANG Jianfeng, ZUO Bin, YANG Binghua, Clinical Laboratory, First Affiliated Hospital, Soochow University, Jiangsu Provincial Institute of Hematology, Cyrus Tang Hematology Research Center, Soochow University …… page:106-111 Screening of special sc Fv antibody against human p53 protein by yeast two-hybrid system (用酵母双杂交系统筛选抗人p53单链抗体) ZHENG Meiyun, LI Miaojun, SHEN Guoying, LIN Suying, LI Huibo, MENG Chun, WANG Hang, College of Biological Science and Engineering, Fuzhou University …… page:112-117 cd258(light) zai zhong liu mian yi zhi liao zhong de yan jiu jin zhan (CD258(LIGHT)在肿瘤免疫治疗中的研究进展) LI Quan, LI Tao, LI Ruipeng, LIU Jianhe …… page:118-121 zhong liu wei huan jing zhong sui xi lai yuan yi zhi xi bao dui t xi bao mian yi huo xing yi zhi de fen zi ji zhi (肿瘤微环境中髓系来源抑制细胞对T细胞免疫活性抑制的分子机制) CHEN Jieying, YU Jinpu …… page:122-124+128 microrna diao kong cd4~+t lin ba xi bao fen hua yu cheng shu de ji zhi yan jiu jin zhan (microRNA调控CD4~+T淋巴细胞分化与成熟的机制研究进展) TANG Qingqin, QIN Baodong, ZHONG Renqian …… page:125-128 ti wai zhuan lu xin shi rna mian yi liao fa de yan jiu jin zhan (体外转录信使RNA免疫疗法的研究进展) LV Jianjun, DUAN Dazuo, JIANG Shuai, YANG Yang …… page:129-132 zu zhi ding ju ju shi xi bao qi yuan ji wen tai wei chi he gong neng yan jiu jin zhan (组织定居巨噬细胞起源及稳态维持和功能研究进展) TAO Huan, BAI Jian, GAO Chunchen, HAN Zuo, QIN Hongyan …… page:133-135+139 toll yang shou ti 4 yu xiao chang que xue de yan jiu jin zhan (Toll样受体4与小肠缺血的研究进展) LIU Shengzhi, ZHOU Xiangyu …… page:136-139 cxc qu hua yin zi pei ti 10(cxcl10) zai lang chuang shen yan zhong zuo yong de yan jiu jin zhan (CXC趋化因子配体10(CXCL10)在狼疮肾炎中作用的研究进展) LIN Qiuping, ZHU Xianjin, LIN Qing …… page:140-142 CAOD TOC Alerts Note Thank you for choosing CAOD Table of Contents (TOC) Alert Service. You are receiving this email because you have requested to receive information from CAOD as a registered user of our Table of Content Alert for journals. To manage your TOC Alerts, please click here. For all enquiries, problems or suggestions regarding this service, please contact info. China/Asia on Demand (CAOD) Customer Service

from Gmail
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QCpnzz
via IFTTT